IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v11y2020i1d10.1038_s41467-020-19819-1.html
   My bibliography  Save this article

Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform

Author

Listed:
  • Flavia Chiuppesi

    (City of Hope National Medical Center)

  • Marcela d’Alincourt Salazar

    (City of Hope National Medical Center)

  • Heidi Contreras

    (City of Hope National Medical Center)

  • Vu H. Nguyen

    (City of Hope National Medical Center)

  • Joy Martinez

    (City of Hope National Medical Center)

  • Yoonsuh Park

    (City of Hope National Medical Center)

  • Jenny Nguyen

    (City of Hope National Medical Center)

  • Mindy Kha

    (City of Hope National Medical Center)

  • Angelina Iniguez

    (City of Hope National Medical Center)

  • Qiao Zhou

    (City of Hope National Medical Center)

  • Teodora Kaltcheva

    (City of Hope National Medical Center)

  • Roman Levytskyy

    (City of Hope National Medical Center)

  • Nancy D. Ebelt

    (Beckman Research Institute of the City of Hope)

  • Tae Hyuk Kang

    (Integrative Genomics Core, Beckman Research Institute of the City of Hope)

  • Xiwei Wu

    (Integrative Genomics Core, Beckman Research Institute of the City of Hope)

  • Thomas F. Rogers

    (University of California San Diego, School of Medicine
    Scripps Research, Department of Immunology and Microbiology)

  • Edwin R. Manuel

    (Beckman Research Institute of the City of Hope)

  • Yuriy Shostak

    (Research Business Development, City of Hope)

  • Don J. Diamond

    (City of Hope National Medical Center)

  • Felix Wussow

    (City of Hope National Medical Center)

Abstract

Modified Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and cancer. We demonstrate the construction of a vaccine platform based on a unique three-plasmid system to efficiently generate recombinant MVA vectors from chemically synthesized DNA. In response to the ongoing global pandemic caused by SARS coronavirus-2 (SARS-CoV-2), we use this vaccine platform to rapidly produce fully synthetic MVA (sMVA) vectors co-expressing SARS-CoV-2 spike and nucleocapsid antigens, two immunodominant antigens implicated in protective immunity. We show that mice immunized with these sMVA vectors develop robust SARS-CoV-2 antigen-specific humoral and cellular immune responses, including potent neutralizing antibodies. These results demonstrate the potential of a vaccine platform based on synthetic DNA to efficiently generate recombinant MVA vectors and to rapidly develop a multi-antigenic poxvirus-based SARS-CoV-2 vaccine candidate.

Suggested Citation

  • Flavia Chiuppesi & Marcela d’Alincourt Salazar & Heidi Contreras & Vu H. Nguyen & Joy Martinez & Yoonsuh Park & Jenny Nguyen & Mindy Kha & Angelina Iniguez & Qiao Zhou & Teodora Kaltcheva & Roman Levy, 2020. "Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform," Nature Communications, Nature, vol. 11(1), pages 1-16, December.
    • Handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-19819-1
    DOI: 10.1038/s41467-020-19819-1
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-020-19819-1
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-020-19819-1?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-19819-1. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.